ArticlePakistan journal of medical sciences2025
Value of serum NT proBNP, HMGB1, and SIRT1 in the diagnosis and prognosis of neonatal respiratory distress syndrome.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on biomarkers associated with neonatal respiratory distress syndrome.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the value of serum aminoterminal pro-brain natriuretic peptide (NT-proBNP), High mobility group protein B1(HMGB1), and silent information regulator factor 2 related enzyme 1 (SIRT1) in the diagnosis and prognosis of neonatal respiratory distress syndrome (NRDS). Methods: This was a retrospective study. Eighty cases of NRDS infants were selected in Maternity & Child Care Center of Qinhuangdao from January 2022 to January 2024 as the study group, with 80 cases of normal newborns during the same period selected as the control group. The NRDS infants were divided into the excellent prognosis group (n=49) and the poor prognosis group (n=31). The levels of serum NT-proBNP, HMGB1, and SIRT1 were compared among the groups, along with an investigation of the value of these biomarkers for the diagnosis and prognosis of NRDS infants. Results: The study group exhibited higher levels of serum NT-proBNP and HMGB1(P< 0.05) and lower levels of serum SIRT1(P< 0.05) than the control group. The ROC curve analysis suggested that AUC values for serum NT-proBNP, HMGB1, SIRT1, and their combination in the diagnosis of NRDS were 0.903, 0.829, 0.794, and 0.958, respectively. The ROC curve analysis showed that AUC values for serum NT-proBNP, HMGB1, SIRT1, and their combination in predicting poor prognosis in NRDS infants were 0.810, 0.813, 0.741, and 0.935, respectively. Conclusion: The combination of serum NT-proBNP, HMGB1, and SIRT1 may demonstrate a high diagnostic value for NRDS infants, as well as a high predictive value for poor prognosis in such infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.